COG, ACNS1422, Ph2, OL, Newly Dx WNT-Driven Medullo; Reduced Rad + Chemo

Summary

Primary Objective: 1. To estimate the progression-free survival (PFS) of children >/= 3 years of age with WNT-driven average-risk medulloblastoma using reduced craniospinal radiotherapy (CSI) (18 Gy) with a limited target volume boost to the tumor bed of 36 Gy for a total of 54 Gy and reduced chemotherapy approach (no vincristine during radiotherapy and reduced-dose maintenance chemotherapy) and to monitor the PFS for early evidence that the outcome is unacceptable. Secondary Objectives: 1. To prospectively test the hypothesis that DNA methylation profiling will accurately classify WNT-driven medulloblastoma. 2. To prospectively evaluate and longitudinally model the cognitive, social, emotional, behavioral and Quality of Life (QoL) functioning of children who are treated with reduced CSI (18 Gy) with a limited target volume boost to the tumor bed (to a total of 54 Gy) and reduced chemotherapy (reduced cisplatin, vincristine and CCNU).


Inclusion Criteria

  • Patients must be newly diagnosed and have:
  • Eligibility confirmed by rapid central pathology and molecular screening review on APEC14B1:
Show more

Study Location(s)

Cedars-Sinai Cancer at SOCC : Karla Russell

More about this Clinical Trial

Full Title

ACNS1422, A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients

Details
Disease Type/Condition

Brain and Nervous System

Principal Investigator

Majlessipour, Fataneh

Co-Investigators

Nicole Baca

Age Group

Both

Phase

II (Cancer Control)

IRB Number

Pro00051571

ClinicalTrials.gov ID

NCT02724579

Key Eligibility
ClinicalTrials.gov

Contact
Name

Karla Russell

Phone
310-423-6252
Email
karla.russell@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Brain and Nervous System

Principal Investigator

Majlessipour, Fataneh

Age Group

Both

Phase

II (Cancer Control)

IRB Number

ACNS1422

ClinicalTrials.gov ID

NCT02724579

Key Eligibility
ClinicalTrials.gov

Contact
Name

Karla Russell

Phone
310-423-6252
Email
karla.russell@cshs.org
Want to join the study or
learn more?